0001193125-20-158461.txt : 20200702 0001193125-20-158461.hdr.sgml : 20200702 20200602160655 ACCESSION NUMBER: 0001193125-20-158461 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 2 FILED AS OF DATE: 20200602 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Legend Biotech Corp CENTRAL INDEX KEY: 0001801198 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: E9 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: 2101 COTTONTAIL LANE CITY: SOMERSET STATE: NJ ZIP: 08873 BUSINESS PHONE: 732-317-5050 MAIL ADDRESS: STREET 1: 2101 COTTONTAIL LANE CITY: SOMERSET STATE: NJ ZIP: 08873 CORRESP 1 filename1.htm CORRESP

LOGO

 

2101 Cottontail Lane

Somerset, NJ 08873

    VIA EDGAR

June 2, 2020

U.S. Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Mail Stop 4546

Washington, D.C. 20549

 

Attn:

Ms. Jenn Do

Ms. Lisa Vanjoske

Mr. Jeffrey Gabor

Ms. Celeste Murphy

 

Re:

Legend Biotech Corporation

Registration Statement on Form F-1

File No. 333-238232

Acceleration Request

Requested Date:         Thursday, June 4, 2020

Requested Time:        4:00 P.M. Eastern Daylight Time

Ladies and Gentlemen:

In accordance with Rule 461 under the Securities Act of 1933, as amended, the undersigned registrant (the “Registrant”) hereby requests that the Securities and Exchange Commission (the “Commission”) take appropriate action to cause the above-referenced Registration Statement on Form F-1 (File No. 333-238232) (the “Registration Statement”) to become effective on June 4, 2020, at 4:00 p.m., Eastern Daylight Time, or as soon thereafter as is practicable, or at such later time as the Registrant or its counsel may orally request via telephone call to the staff (the “Staff”).

Once the Registration Statement has been declared effective, please orally confirm that event with Divakar Gupta of Cooley LLP (212) 479-6474, counsel to the Registrant, Robert W. Phillips at (415) 693-2020 or Mark Ballantyne at (703) 456-8084.

Very truly yours,
Legend Biotech Corporation
By:  

/s/ Yuan Xu

  Yuan Xu
  Chief Executive Officer

 

cc:

Yuan Xu, Ph.D., Legend Biotech Corporation

Ying Huang, Ph.D., Legend Biotech Corporation

Robert W. Phillips, Cooley LLP

Richard C. Segal, Cooley LLP

Mark Ballantyne, Cooley LLP

Richard D. Truesdell, Jr., Davis Polk & Wardwell LLP

Yasin Keshvargar, Davis Polk & Wardwell LLP

GRAPHIC 2 g884493dsp_2.jpg GRAPHIC begin 644 g884493dsp_2.jpg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end